Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges

Affiliations

¹ Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, QuirónSalud Group, Viladomat 288, 08029 Barcelona, Spain.
² Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Editorial

Niki Karachaliou et al. Ther Adv Med Oncol. 2018.

. 2018 Mar 22:10:1758835918763723.

doi: 10.1177/1758835918763723. eCollection 2018.

¹ Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, QuirónSalud Group, Viladomat 288, 08029 Barcelona, Spain.
² Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

No abstract available

Keywords: anti-PD-1/PD-L1; biomarkers; combinations; immunotherapy; lung cancer.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

1. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293–12297. - PMC - PubMed
1. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793–800. - PubMed
1. Antonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016; 17: 883–895. - PubMed
1. Hellmann M, Antonia S, Ponce S, et al. MA09.05 Nivolumab alone or with ipilimumab in recurrent Small Cell Lung Cancer (SCLC): 2-year survival and updated analyses from the Checkmate 032 trial. J Thorac Oncol 2017; 12: S393–S394.
1. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 2017; 35: 3924–3933. - PMC - PubMed